Medicare's $35 Insulin Cost Cap Boosts Basal Insulin Persistence by 1.3 Percentage Points
Background
Poor medication adherence, particularly for essential therapies like insulin, is a major challenge in managing Type 2 Diabetes and other conditions requiring insulin. High out-of-pocket costs are a significant barrier, often leading to patients rationing or discontinuing their medication, which exacerbates glycemic control issues and increases the risk of serious complications. The Medicare Part D program, while providing prescription drug coverage, previously exposed beneficiaries to substantial insulin costs. Addressing this financial burden through policy changes like cost caps is crucial for improving treatment access and patient outcomes.
Study Design
Researchers conducted a retrospective cohort analysis using a nationally representative Medicare Advantage sample from 2022 to 2023. They compared rates of Persistence to Basal Insulin in the pre-cap period (2022) with post-cap rates (2023) following the implementation of the $35 monthly out-of-pocket cost cap for insulin. The study population included Medicare beneficiaries using basal insulin, with subgroup analyses performed across demographics (age, sex, race) and geographic regions to identify differential impacts of the cost cap.
Results
The implementation of the insulin cost cap was associated with a statistically significant increase in overall patient persistence to basal insulin. In its first year, persistence rose by +1.3 percentage points (P < .001). This improvement indicates that reducing financial barriers directly translates to better medication adherence. Subgroup analyses revealed even greater increases in persistence among specific populations, highlighting the policy's impact on addressing health disparities. Notably, patients aged 45 to 54 and 65 to 74 years, male patients, and non-Hispanic Black patients showed more pronounced increases in persistence.
The $35 monthly out-of-pocket cost cap for insulin led to a statistically significant +1.3 percentage points increase in overall patient persistence to basal insulin (P<.001) in its first year. Further, patients residing in certain census divisions, particularly those with a high prevalence of type 2 diabetes, also experienced greater improvements in their basal insulin persistence rates.
Key Findings
- Overall patient persistence to basal insulin increased by +1.3 percentage points (P < .001) after the cost cap.
- Greater increases in persistence were observed in patients aged 45 to 54 and 65 to 74 years.
- Male patients showed a more significant increase in basal insulin persistence.
- Non-Hispanic Black patients experienced greater improvements in persistence.
- Patients in high type 2 diabetes prevalence census divisions also saw larger increases.
Why It Matters
The Medicare insulin cost cap directly improves patient adherence to basal insulin, potentially leading to better health outcomes and reduced economic burden for beneficiaries. This study provides compelling evidence that policy interventions aimed at reducing out-of-pocket medication costs can significantly enhance treatment persistence. For clinicians, this suggests that addressing financial barriers is as critical as clinical management in achieving optimal patient outcomes. The findings offer valuable insights for future policy evaluations and proposals, demonstrating a clear pathway to improve medication access and address disparities in appropriate medication use, ultimately moving closer to a healthcare system where cost is not a barrier to essential care.
medicare
insulin
cost-cap
diabetes
adherence
health-policy